Astellas Pharma Inc (ALPMF PINK) stock market data APIs
$16.4311
0(0%)
as of February 20, 2026
Try our APIs with
free plan!
Astellas Pharma Inc Financial Data Overview
Price chart is built with
Anychart
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration; EVRENZO, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize an integrated diabetes self-management solution. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Prev. Close
16.4311
Open
16.4311
High
16.4311
Low
16.4311
52 wk Range
8.405-17.39
Market Cap
29 280 M
P/E Ratio
37.3256
Shares Outstanding
1 791 M
Revenue
2 060 614 M
EPS
0.3625
Dividends (Yield)
0.0337
Beta
0.044
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Astellas Pharma Inc data using free add-ons & libraries
Get Astellas Pharma Inc Fundamental Data
Astellas Pharma Inc Fundamental data includes:
- Net Revenue: 2 060 614 M
- EBITDA: 608 504 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-04
- EPS/Forecast: 8.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Astellas Pharma Inc News
New
Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development
BAAR, Switzerland, February 18, 2026--(BUSINESS WIRE)--Evinova today announced strategic collaborations with global life sciences companies Astellas Pharma Inc. ("Astellas"), AstraZeneca and Bristol M...
Is It Too Late To Consider Astellas Pharma (TSE:4503) After An 83% One-Year Rally?
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. If you are wondering whether Astellas Pharma's share price still offers value a...
India's Zydus Life agrees $120 million settlement with Astellas over bladder drug
Feb 12 (Reuters) - India's Zydus Lifesciences and its U.S. unit will pay $120 million to Astellas Pharma as part of a deal to settle a patent dispute over the Japanese drugmaker's bladder dis...
PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight
The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical...
Get Astellas Pharma Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
